BIO-Europe 2010

BIO-Europe is Europe's largest partnering conference, serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry.

Leaders of the life science industry will gather in Munich, Germany, November 15–17 for the 16th annual BIO-Europe partnering conference. The three-day event will host more than 2,500 attendees representing about 1,400 companies who will engage in over 13,000 one-to-one meetings.

In addition to the many panels and workshops devoted to effective partnering and development strategies, BIO-Europe 2010 features a plenary session focusing on the topic of personalized medicine. As the winner of Germany’s top cluster prize, Munich is a perfect backdrop for exploring the significant implications that the shift to personalized medicine brings.

“The timing of BIO-Europe in Munich this year could not be better,” said Horst Domdey, Managing Director of BioM. “It is like a beautiful piece of choreography, because at this very moment we can make a very convincing demonstration that the promise of personalized medicine has at last reached its first flowering.”

Domdey added, “All the major biotechnology and pharmaceutical companies will be at BIO-Europe, so we are making sure that all the viable companies from Munich and Bavaria will also be present.”

In the opening plenary session, “Personalized Medicine and Its Implications for Pharma, Biotech and Diagnostic Companies”, moderator Frank L. Douglas, Austen BioInnovation Institute in Akron, will lead panelists Andreas Fibig, Bayer Schering Pharma AG; Loïc Maurel, Exonhit Therapeutics; and Olaf G. Wilhelm, WILEX AG in a discussion of how drug development firms can succeed in the emerging personalized healthcare regime.